|
|||||
|
|
Recent advances in mRNA-based vaccine for cancer therapy; bench to bedside |
|
| Authors: | Hadeel Ahmed Kenoosh Harikumar Pallathadka Ahmed Hjazi Aiman Mohammed Baqir Al-Dhalimy Sajad Ali Zearah Pallavi Ghildiyal Zuhair I. Al-Mashhadani Yasser Fakri Mustafa Manar Mohammed Hizam Ahmed Elawady |
| Affiliation: | 1. Department of Medical Laboratory Techniques, Al-Maarif University College, AL-Anbar, Iraq;2. Manipur International University, Imphal, Manipur, India;3. Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia;4. Department of Nursing, Altoosi University College, Najaf, Iraq;5. Scientific Research Center, Al-Ayen University, Thi-Qar, Iraq;6. Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India;7. Anesthesia Techniques, Al-Nisour University College, Baghdad, Iraq;8. Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq;9. College of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq;10. College of Technical Engineering, The Islamic University, Najaf, Iraq College of Technical Engineering, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq College of Technical Engineering, The Islamic University of Babylon, Babylon, Iraq |
| Abstract: | The messenger RNA (mRNA) vaccines have progressed from a theoretical concept to a clinical reality over the last few decades. Compared to conventional vaccination methods, these vaccines have a number of benefits, such as substantial potency, rapid growth, inexpensive production, and safe administration. Nevertheless, their usefulness was restricted up to now due to worries about the erratic and ineffective circulation of mRNA in vivo. Thankfully, these worries have largely been allayed by recent technological developments, which have led to the creation of multiple mRNA vaccination platforms for cancer and viral infections. The mRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low-cost manufacturing. The paper will examine the present status of mRNA vaccine technology and suggest future paths for the advancement and application of this exciting vaccine platform as a common therapeutic choice. |
| Keywords: | cancer immunotherapy mRNA vaccines platforms |